SCHEMBL6490937

SCHEMBL6490937

O=C1CC(C(=O)N2CCC(c3ccccc3)CC2)CCc2c(O)cccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.43
HTR2B P41595 1/20 0.42
SPR P35270 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
MAPK1 P28482 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
KCNH2 Q12809 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC18A3 Q16572 2/20 0.38
NPC1 O15118 1/20 0.38
CCR5 P51681 2/20 0.38
SCD5 Q86SK9 1/20 0.38
ADAM10 O14672 1/20 0.38
ERBB2 P04626 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499095 0.89 HTR2B (0.44) BACE1HTR2BSIGMAR1MAPK1KCNH2
SCHEMBL6499625 0.89 SPR (0.43) BACE1HTR2BSPRSIGMAR1MAPK1
SCHEMBL6501862 0.88 BACE1 (0.42) BACE1HTR2BSPRSIGMAR1MAPK1
SCHEMBL6490907 0.88 BACE1 (0.47) BACE1HTR2BSPRSIGMAR1MAPK1
SCHEMBL6499841 0.88 NPC1 (0.42) BACE1HTR2BSIGMAR1MAPK1KCNH2
SCHEMBL6079726 0.86 KMT2A (0.40) KCNH2
SCHEMBL6075908 0.85 KMT2A (0.48) SMN1; SMN2NPC1CCR5
SCHEMBL6493038 0.83 BACE1 (0.46) BACE1HTR2BMAPK1KCNH2HRH3
SCHEMBL6490895 0.81 HTT (0.46) SMN1; SMN2
SCHEMBL6490446 0.79 BACE1 (0.41) BACE1HTR2BSPRKCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969724-B2 Compounds SMITHKLINE BEECHAM-SPA (GB) 2005-11-29 US disclosed
US-20050234096-A1 Tetrahydroisoquinoline derivatives BAYER HEALTHCARE AG (DE) 2005-10-20 US disclosed
US-20040024218-A1 Novel compounds SMITHKLINE BEECHAM SPA 2004-02-05 US disclosed
EP-1129072-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS Smithkline Beecham S.p.A. (IT) 2001-09-05 EP disclosed
WO-2000027815-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS SMITHKLINE BEECHAM SPA (IT) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024218-A1 Novel compounds OXER1, CLIC1, CCR1 BACE1 3422/4885HTR2B 1592/4885SPR 4663/4885
US-20050234096-A1 Tetrahydroisoquinoline derivatives PPARD, PPARG, PPARA BACE1 1209/4885HTR2B 1107/4885SPR 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.